AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 38710920
Drug: Nuvastatic™ 1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nuvastatic™ 1000 mg thrice daily for 9 weeks
Trial: 38710996
Drug: Metronomic capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Metronomic capecitabine (650 mg/m² twice daily for 1 year)
Trial: 38711253
Drug: Venetoclax plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venetoclax plus azacitidine (75 mg/m²)
Trial: 38712176
Drug: Consolidation doublet
RxNorm normalized name: BAG,LEG LARGE CONSOLIDATED #0932
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Consolidation doublet chemotherapy (mFOLFOX6 or CAPOX) after neoadjuvant long course chemoradiation (LCRT)
Trial: 38712176
Drug: Consolidation triplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Consolidation triplet chemotherapy (mFOLFIRINOX) after neoadjuvant long course chemoradiation (LCRT)
Trial: 38712567
Drug: TXT (anti-hypotensive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TXT (anti-hypotensive therapy)
Trial: 38712616
Drug: Dendritic cell
RxNorm normalized name: Dendritic cells vaccine
DrugBank: Dendritic cells vaccine (DB15803)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dendritic cell vaccines
Trial: 38713205
Drug: Surufatinib (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surufatinib (250 mg orally, once daily) plus toripalimab (240 mg intravenously, once every three weeks)
Trial: 38713500
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) for PVCs, delivered over 10 weeks via videoconference with online text-based information and homework assignments.
Trial: 38713500
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) for PVCs
Trial: 38713595
Drug: Ciltacabtagene autoleucel
RxNorm normalized name: ciltacabtagene autoleucel
DrugBank: Ciltacabtagene autoleucel (DB16738)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciltacabtagene autoleucel (CAR T-cell therapy)
Trial: 38713888
Drug: Mass spectrometry
RxNorm normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mass spectrometry (MS) assessment of measurable residual disease (MRD) negativity during posttransplant therapy
Trial: 38713894
Drug: Synthetic long
RxNorm normalized name: Human Papilloma Virus (HPV) Type 16 E6/E7 Synthetic Long Peptide (SLP) Vaccine Component L-3972-T
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synthetic long peptide vaccines targeting predicted high-quality neoantigens
Trial: 38714422
Drug: topical promestriene
RxNorm normalized name: promestriene
DrugBank: Promestriene (DB12487)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical promestriene for 90 days (n=17)
Trial: 38714422
Drug: fractional CO2
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fractional CO2 laser treatment (n=24)
Trial: 38714422
Drug: microablative fractional
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: microablative fractional radiofrequency treatment (n=21)
Trial: 38714786
Drug: THC (10-80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: THC (10-80 mg, individually dosed)
Trial: 38714924
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of 1% lidocaine
Trial: 38714999
Drug: Selenium yeast
RxNorm normalized name: Selenium Yeast
DrugBank: Selenium (DB11135)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selenium yeast (200 µg/day) and coenzyme Q
Trial: 38715140
Drug: Autologous adipose
RxNorm normalized name: Autologous adipose derived mesenchymal stromal cells
DrugBank: Autologous adipose derived mesenchymal stromal cells (DB17925)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous adipose tissue-derived mesenchymal stem cell (AD-MSC) transplantation (2 infusions of 100 million cells i.v)
Trial: 38715621
Drug: Immune tolerance
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immune tolerance induction (ITI) therapy with bortezomib, rituximab, methotrexate, and intravenous immunoglobulin over 6 months
Trial: 38715621
Drug: Immune tolerance
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immune tolerance induction (ITI) therapy
Trial: 38716419
Drug: Ciprofol (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofol (0.4 mg/kg for induction and 0.2 mg/kg for maintenance)
Trial: 38716419
Drug: Propofol (2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (2.0 mg/kg for induction and 1.0 mg/kg for maintenance)
Trial: 38717075
Drug: D3S-001, a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D3S-001, a next-generation GDP-bound G12C inhibitor
Trial: 38717075
Drug: Sotorasib and
RxNorm normalized name: sotorasib
DrugBank: Sotorasib (DB15569)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sotorasib and adagrasib (first-generation KRAS G12C inhibitors)
Trial: 38717556
Drug: No beta
RxNorm normalized name: Amidino beta-alanine
DrugBank: Ompenaclid (DB18819)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No beta blockers
Trial: 38717773
Drug: Rapid procedure
RxNorm normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid procedure (RP): 1 day of buprenorphine at minimum necessary dose, 1 opioid-free day, ascending low doses of oral naltrexone and adjunctive medications
Trial: 38717773
Drug: Standard procedure
RxNorm normalized name: HOMOSALATE 60 mg in 1 mL / OCTOCRYLENE 30 mg in 1 mL / ZINC OXIDE 80 mg in 1 mL TOPICAL STICK [Standard Procedure Lip Balm SPF 50]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard procedure (SP): approximately 5-day buprenorphine taper followed by a 7- to 10-day opioid-free period
Trial: 38717861
Drug: Intensive chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive chemotherapy (IC) 3+7
Trial: 38717993
Drug: Neoadjuvant nivolumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant nivolumab with chemotherapy
Trial: 38717997
Drug: High-intensity interval
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-intensity interval training (three sessions weekly for 8 weeks)
Trial: 38718169
Drug: Daily Examen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily Examen prayer practice
Trial: 38718683
Drug: Aromatase inhibitors
RxNorm normalized name: Aromatase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aromatase inhibitors (AI) intake
Trial: 38718683
Drug: Multivariable analysis
RxNorm normalized name: Chemicals and reagents for analysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multivariable analysis of ET intake timing and ET agent
Trial: 38718923
Drug: Machine learning
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Machine learning (ML) and Artificial Intelligence (AI) model
Trial: 38718924
Drug: Total Iodine
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total Iodine Excretion (TIE)
Trial: 38718924
Drug: Urinary Iodine
RxNorm normalized name: Iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Urinary Iodine Excretion Rate (UIER)
Trial: 38718924
Drug: Breast Milk
RxNorm normalized name: BREAST MILK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Breast Milk Iodine Excretion Rate (BMIER)
Trial: 38718924
Drug: Effect of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Effect of TII on BMIER when TII <120 μg/d
Trial: 38719277
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy (carboplatin and paclitaxel in a 3 weekly scheme) followed by surgery
Trial: 38719277
Drug: Primary chemoradiation
RxNorm normalized name: Sodium primary phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary chemoradiation (tumor dose of 64.5 Gy in 30 fractions of external beam radiotherapy with weekly cisplatin for 6 weeks)
Trial: 38719280
Drug: Androgenic anabolic
RxNorm normalized name: ANDROGENS/ANABOLICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androgenic anabolic steroids (AAS) use
Trial: 38719313
Drug: Calcium dobesilate
RxNorm normalized name: CALCIUM DOBESILATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium dobesilate (CaD) 500 mg, two capsules two times per day for 7 days
Trial: 38719313
Drug: Placebo (mannitol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (mannitol 312.5 mg), two matching capsules two times per day for 7 days
Trial: 38719544
Drug: YSCH-01 (Recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YSCH-01 (Recombinant L-IFN adenovirus)
Trial: 38719803
Drug: Primaquine (0.25-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primaquine (0.25-1 mg base/kg once daily given to the mother for 1-14 days)
Trial: 38720363
Drug: SBIRT (Screening,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SBIRT (Screening, Brief Intervention and Referral to Treatment) delivered by trained lay health workers, followed by referral to treatment with varenicline prescribed and monitored by trained nurse prescribers.
Trial: 38720383
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose rifampicin (35 mg/kg/day) plus levofloxacin added to standard TB treatment for the first 14 days
Trial: 38720383
Drug: Adjunctive corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive corticosteroids (prednisone 1.5 mg/kg/day) for the first 14 days of TB treatment
Trial: 39622823
Drug: Standard tuberculosis
RxNorm normalized name: Mycobacterium tuberculosis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard tuberculosis treatment
Trial: 38720661
Drug: Cafedrine/theodrenaline (C/T)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cafedrine/theodrenaline (C/T) combination (20:1)
Trial: 38720913
Drug: 4-week low-frequency
RxNorm normalized name: milnacipran
DrugBank: Milnacipran (DB04896)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4-week low-frequency rTMS targeting the right dorsolateral prefrontal cortex (rDLPFC) + treatment as usual (TAU) (n = 25)
Trial: 38720913
Drug: Sham stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham stimulation + treatment as usual (TAU) (n = 25)
Trial: 38720913
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (TAU) only (for low FCR group)
Trial: 38720913
Drug: Post-treatment fMRI
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Post-treatment fMRI scan
Trial: 38721015
Drug: Chemotherapy followed
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chemotherapy followed by liver transplantation (LT)
Trial: 38721358
Drug: Selumetinib 25
RxNorm normalized name: selumetinib 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selumetinib 25 mg/m administered with a low-fat meal
Trial: 38721358
Drug: Selumetinib 25
RxNorm normalized name: selumetinib 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selumetinib 25 mg/m administered in a fasted state
Trial: 38721402
Drug: Lacnotuzumab (MCS110)
RxNorm normalized name: dalotuzumab
DrugBank: Lacnotuzumab (DB14928)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lacnotuzumab (MCS110) in combination with Spartalizumab (PDR001)
Trial: 38721680
Drug: Oral preparation
RxNorm normalized name: Iron bivalent, oral preparations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral preparation of hyaluronic acid, chondroitin sulfate, N-acetylglucosamine, and vitamin C once a day for 3 months
Trial: 38721680
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received an oral preparation of cranberry, D-mannose, propolis extract, turmeric, and Boswellia twice a day for 3 months
Trial: 38721977
Drug: Automated vertebral
RxNorm normalized name: Sus scrofa cerebral cortex preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Automated vertebral segmentation for low dose CT
Trial: 38721977
Drug: Fracture assessment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fracture assessment from low dose CT
Trial: 38722621
Drug: Ponatinib (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ponatinib (30 mg/d) with reduced-intensity chemotherapy, followed by single-agent ponatinib after cycle 20.
Trial: 38722621
Drug: Imatinib (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imatinib (600 mg/d) with reduced-intensity chemotherapy, followed by single-agent imatinib after cycle 20.
Trial: 38722621
Drug: Ponatinib (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ponatinib (30 mg/d)
Trial: 38722621
Drug: Imatinib (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imatinib (600 mg/d)
Trial: 38722641
Drug: Nivolumab induction
RxNorm normalized name: nivolumab Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab induction (240 mg every 2 weeks)
Trial: 38722641
Drug: Nivolumab +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab + ipilimumab (3 mg/kg + 1 mg/kg, followed by 1 mg/kg + 3 mg/kg)
Trial: 38722641
Drug: Nivolumab +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab + ipilimumab (1 mg/kg + 3 mg/kg)
Trial: 38722641
Drug: Nivolumab +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab + ipilimumab (high-dose)
Trial: 38722664
Drug: Inotuzumab ozogamicin
RxNorm normalized name: Inotuzumab ozogamicin
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Inotuzumab ozogamicin (InO) at 0.6 mg/m2 on day 8 and day 15 of a 28-day cycle combined with DA-EPOCH
Trial: 38722831
Drug: Sit Less
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sit Less program (12-week intervention including goal-setting session, Fitbit, smart water bottle, weekly text messages)
Trial: 38722926
Drug: Mindfulness and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness and acceptance-based intervention (weekly 90-minute group sessions for four consecutive weeks)
Trial: 38723189
Drug: GnRH agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonist protocol with individualized fixed daily dose of follitropin delta
Trial: 38723189
Drug: GnRH antagonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH antagonist protocol with individualized fixed daily dose of follitropin delta
Trial: 38723227
Drug: Nivolumab +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab + relatlimab + chemotherapy
Trial: 38723227
Drug: Nivolumab +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab + chemotherapy
Trial: 38723373
Drug: encorafenib 450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: encorafenib 450 mg QD plus binimetinib 45 mg BID
Trial: 38723373
Drug: vemurafenib 960
RxNorm normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: vemurafenib 960 mg BID
Trial: 38723373
Drug: encorafenib monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: encorafenib monotherapy 300 mg QD
Trial: 38723644
Drug: Maralixibat (starting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maralixibat (starting dose 142.5 μg/kg, then escalated to 570 μg/kg)
Trial: 38724058
Drug: Intravenous injections
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injections of ICG twice with intraoperative assessment of anastomotic blood flow using the near-infrared NIR-ICG system during total mesorectal excision (TME) surgery.
Trial: 38724293
Drug: felcisetrag 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: felcisetrag 0.5 mg daily
Trial: 38724293
Drug: felcisetrag 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: felcisetrag 0.5 mg pre-surgery
Trial: 38724531
Drug: Prior treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prior treatment with second-line drugs
Trial: 38724605
Drug: Delayed fortification
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed fortification at 80 ml/kg/day
Trial: 38724874
Drug: Intensive antihypertensive
RxNorm normalized name: ANTIHYPERTENSIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive antihypertensive treatment (AHT) targeting systolic blood pressure (SBP) ≤140 mmHg for a median duration of 7 weeks
Trial: 38724874
Drug: Intensive antihypertensive
RxNorm normalized name: ANTIHYPERTENSIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive antihypertensive treatment (AHT)
Trial: 38724991
Drug: Molecularly guided
RxNorm normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Molecularly guided treatment (MGT) informed by molecular tumor boards (MTBs)
Trial: 38724991
Drug: Tier 1:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tier 1: Therapeutic use of investigational drugs targeting genetic alterations (e.g., ALK, EGFR, ERBB2, BRAF, FH, ROS1, RET)
Trial: 38724991
Drug: Tier 2:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tier 2: Drugs with approved indications or permitted for treatment outside of approved indications
Trial: 38725194
Drug: Intraovarian PRP
RxNorm normalized name: HEMOPHILUS B PRP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraovarian PRP injection
Trial: 38725258
Drug: Matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo D/C/F/TAF tablets
Trial: 38725258
Drug: Matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo D/C/TAF tablets
Trial: 38725995
Drug: High-dose encorafenib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose encorafenib 300 mg BID plus binimetinib 45 mg BID
Trial: 38725995
Drug: Standard-dose encorafenib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose encorafenib 450 mg QD plus binimetinib 45 mg BID
Trial: 38725995
Drug: Escalated dose
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escalated dose encorafenib 600 mg QD plus binimetinib 45 mg BID
Trial: 38726365
Drug: Batiraxcept in
RxNorm normalized name: Batiraxcept
DrugBank: Batiraxcept (DB17522)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Batiraxcept in combination with durvalumab
Trial: 38727837
Drug: Camrelizumab (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Camrelizumab (200 mg once every 3 weeks via intravenous infusion) plus famitinib (20 mg once daily)
Trial: 38728033
Drug: Blood pressure
RxNorm normalized name: Blood Pressure Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood pressure self-monitoring plus medication self-titration
Trial: 38728603
Drug: Patients taking
RxNorm normalized name: Lamictal Blue (For Patients Taking Valproate)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients taking treatment for substance use disorder
Trial: 38728925
Drug: Heparin-mediated extracorporeal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-mediated extracorporeal LDL-precipitation (HELP)-apheresis
Trial: 38729196
Drug: MVA-NP+M1 (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MVA-NP+M1 (0.5 mL intramuscular injections of modified vaccinia Ankara expressing H3N2 nucleoprotein and matrix protein 1)
Trial: 38729399
Drug: Cotadutide 600
RxNorm normalized name: Cotadutide
DrugBank: Cotadutide (DB15194)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cotadutide 600 μg
Trial: 38729426
Drug: Subcutaneous atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subcutaneous atezolizumab (1875 mg)
Trial: 38729426
Drug: Intravenous atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous atezolizumab (1200 mg)
Trial: 38729636
Drug: Control (usual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (usual therapy without spironolactone)
Trial: 39297052
Drug: Rozanolixizumab 10
RxNorm normalized name: Rozanolixizumab
DrugBank: Rozanolixizumab (DB14919)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rozanolixizumab 10 mg/kg
Trial: 38729748
Drug: Erythropoietin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythropoietin (500 U/kg daily) for 9 days
Trial: 38729748
Drug: Placebo (sham
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (sham injections)
Trial: 38729754
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment with reconstructive lymphatic surgery
Trial: 38729754
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment alone (control group)
Trial: 38729756
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (no cerclage)
Trial: 38729951
Drug: Fosfomycin, flomoxef,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosfomycin, flomoxef, and amikacin (combination regimens)
Trial: 38730030
Drug: Guided internet-delivered
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guided internet-delivered psychodynamic therapy (IPDT)
Trial: 38730030
Drug: Unguided internet-delivered
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unguided internet-delivered psychodynamic therapy (IPDT)